A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0873 in Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2014
At a glance
- Drugs MK 0873 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 03 Nov 2009 Actual patient number (106) added and official title amended as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.